Summary
This multicentre clinical trial investigated the efficacy of neoadjuvant atezolizumab, a PD-L1 inhibitor, in patients with muscle-invasive bladder cancer who could not tolerate or were ineligible for standard cisplatin-based chemotherapy. The study assessed pathological response rates and safety outcomes as a potential alternative treatment approach for this medically complex patient population. The findings contribute to evidence on immunotherapy as a neoadjuvant strategy in bladder cancer management.
UK applicability
The results are directly relevant to UK oncology practice, as the NHS treats bladder cancer patients with similar cisplatin-ineligibility profiles. The findings may inform National Cancer Institute or NICE guidance on immunotherapy use in neoadjuvant settings for bladder cancer.
Key measures
Pathological complete response rate, major pathological response, safety and tolerability profiles, biomarkers of immune response
Outcomes reported
The study reported efficacy and safety outcomes of neoadjuvant atezolizumab (an anti-PD-L1 immunotherapy) in patients with muscle-invasive urothelial bladder cancer who were ineligible for cisplatin-based chemotherapy. Primary endpoints likely included pathological complete response rates and clinical outcomes at cystectomy.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.